Home » Topics » BioWorld Science, Nephrology

BioWorld Science, Nephrology
RSS

FDA grants orphan drug designation to Amyndas Pharmaceuticals' Compstatin 40

Nov. 18, 2015

ProMetic reveals agent under development for diabetic nephropathy

Nov. 18, 2015

Sophiris Bio reports results from phase III trial of PRX-302 in BPH

Nov. 13, 2015

Antagonism of CCR2/5 in type 2 diabetic nephropathy

Nov. 9, 2015

SUL-121, a novel candidate to treat diabetic nephropathy

Nov. 9, 2015

Preclinical toxicity study results for Pyridorin will support planned IND filing

Nov. 9, 2015

Quark Pharmaceuticals plans new trials of QPI-1002

Nov. 3, 2015

Isis Pharmaceuticals begins phase II study of ISIS-FXIRx in end-stage renal disease

Nov. 3, 2015

Taiho starts phase I trial of TAS-303 in women with stress urinary incontinence

Nov. 3, 2015

Revive Therapeutics' bucillamine receives orphan drug designation for cystinuria

Oct. 30, 2015

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...